These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36990322)

  • 1. Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Aug; 130(8):795-803. PubMed ID: 36990322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS® Registry.
    MacCumber MW; Wykoff CC; Karcher H; Adiguzel E; Sinha SB; Vishwakarma S; LaPrise A; Igwe F; Freitas R; Ip MS; Zarbin MA
    Ophthalmology; 2023 Sep; 130(9):937-946. PubMed ID: 37086857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
    Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
    Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
    Coney JM; Zubricky R; Sinha SB; Sonbolian N; Zhou L; Hull TP; Lewis SA; Miller DG; Novak MA; Pendergast SD; Pham H; Platt SM; Rao LJ; Schartman JP; Singerman LJ; Donkor R; Fink M; McCoy J; Karcher H
    Int J Retina Vitreous; 2023 Feb; 9(1):8. PubMed ID: 36726178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
    Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
    Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
    Dugel PU; Koh A; Ogura Y; Jaffe GJ; Schmidt-Erfurth U; Brown DM; Gomes AV; Warburton J; Weichselberger A; Holz FG;
    Ophthalmology; 2020 Jan; 127(1):72-84. PubMed ID: 30986442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
    Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
    Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
    Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
    Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
    Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
    Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
    Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
    Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
    Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
    JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
    Khanani AM; Zarbin MA; Barakat MR; Albini TA; Kaiser PK; B G; Agashivala N; Yu JS; Wykoff CC; MacCumber MW
    JAMA Ophthalmol; 2022 Jan; 140(1):20-28. PubMed ID: 34817566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
    Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
    Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
    Matsumoto H; Hoshino J; Nakamura K; Akiyama H
    Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
    Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study.
    Bulirsch LM; Saßmannshausen M; Nadal J; Liegl R; Thiele S; Holz FG
    Br J Ophthalmol; 2022 Sep; 106(9):1288-1294. PubMed ID: 33846161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the uninjected contralateral eye after intravitreal brolucizumab for exudative age-related macular degeneration.
    Mora P; Bellucci C; Radice LM; Manzotti F; Gandolfi S
    Eur J Ophthalmol; 2024 Jan; 34(1):NP104-NP107. PubMed ID: 37424299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.